Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus : A Cost-Utility Analysis by Dawoud, Dalia et al.
 
 
 
 
 
Citation for the published version:  
 
Dawoud, D., Fenu, E., Higgins, B., Wonderling, D., & Amiel, S. A. (2017). Basal 
Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. 
Value in health : the journal of the International Society for Pharmacoeconomics and 
Outcomes Research, 20(10), 1279-1287. DOI: 10.1016/j.jval.2017.05.021 
 
Document Version:  Accepted Version 
 
This manuscript is made available under the CC-BY-NC-ND license 
https://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
Link to the final published version available at the publisher:  
 
https://doi.org/10.1016/j.jval.2017.05.021  
 
 
 
 
 
 
General rights 
Copyright© and Moral Rights for the publications made accessible on this site are retained by the 
individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied and it is a 
condition of accessing publications that users recognise and abide by the legal requirements 
associated with these rights. You may not engage in further distribution of the material for any 
profitmaking activities or any commercial gain. You may freely distribute both the url 
(http://uhra.herts.ac.uk/) and the content of this paper for research or private study, educational, or 
not-for-profit purposes without prior permission or charge. 
Take down policy 
If you believe that this document breaches copyright please contact us providing details, any such 
items will be temporarily removed from the repository pending investigation. 
Enquiries 
Please contact University of Hertfordshire Research & Scholarly Communications for any enquiries at 
rsc@herts.ac.uk 
1	
	
Abstract 
Objectives  
To assess the cost effectiveness of basal insulin regimens for adults with Type 1 diabetes (T1D) in 
England.  
Methods  
Cost-utility analysis (CUA) was undertaken in accordance with NICE reference case. UK NHS and 
personal and social services (PSS) perspective was used and 3.5% discount rate applied for both 
costs and outcomes. Relative effectiveness estimates were based on a systematic review of 
published trials and a Bayesian network meta-analysis (NMA). The IMS CORE Diabetes Model 
(CDM) was used, where net monetary benefit (NMB) was calculated using a threshold of £20,000 per 
quality-adjusted life-year (QALY) gained. Wide range of sensitivity analyses was undertaken.  
Results  
Insulin detemir (twice-daily) [iDet (bid)] had the highest mean QALY gain (11.09 QALYs) and NMB 
(£181,456) per patient over the model time horizon. Compared to the lowest cost strategy (insulin 
NPH once daily [iNPH (od)]; it had an incremental cost-effectiveness ratio (ICER) of £7,844 per 
QALY-gained. Insulin glargine (od) [iGlarg (od)] and iDet (od) were ranked as second and third, with 
NMB of £180,893 and £180,423, respectively.  iDet (bid)] remained the most cost-effective treatment 
throughout the sensitivity analyses performed except when high doses were assumed (>30% 
increment compared to other regimens); where in this scenario analysis iGlarg (od) ranked first.  
Conclusions 
 iDet (bid) is the most cost-effective regimen; providing the highest QALY gain and NMB. iGlarg (od) 
and iDet (od) are possible options for those for whom the twice daily regimen of insulin determir is not 
acceptable or does not achieve required glycaemic control. 
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Introduction 
Type 1 diabetes mellitus (T1D) is a long-term hormonal deficiency disorder, caused by autoimmune 
destruction of the insulin-secreting beta cells of the pancreas. This results in high plasma glucose 
concentrations and other metabolic and haematological abnormalities, which have both acute and 
long-term adverse effects. (1) Over the long term, T1D carries risk of major complications and 
reduced life expectancy. (2) 
Approximately 10% of adults diagnosed with diabetes have T1D.	(3) In 2010-2011, the cost of T1D to 
the National Health Service (NHS) was estimated to be around £1 billion, with around 80% due to 
complications. (3) At present there is no cure. The treatment of T1D is insulin replacement therapy 
and this insulin is not under endogenous control. Insulin regimens that reduce and improve the 
stability of glycated haemoglobin (HbA1c), a reflection of average plasma glucose concentrations over 
the medium term (two to three months), are likely to reduce short-term complications such as hypo- 
and hyperglycaemia and also to reduce the occurrence of long-term complications and premature 
mortality.(4-6) 
Basal insulin replacement needs to provide glucose control between meals and overnight, with 
minimal risk of hypoglycaemia. An insulin that has a long and flat duration of action is expected to be 
optimal for basal replacement, and minimising the numbers of injections required to provide basal 
cover that reliably lasts at least 24 hours is desirable. Current basal insulin regimens in common use 
in the United Kingdom (UK) include the human intermediate acting insulins, such as the isophane or 
Neutral Protamine Hagedorn (iNPH) insulins (human, porcine or bovine); the insulin analogues insulin 
detemir (iDet) and insulin glargine (iGlarg), which have flatter ‘peakless’ insulin action profiles, (7;8) 
and more recently the very long-acting insulin insulin degludec (iDegl).(9) Each new basal insulin 
analogue has data to suggest less day to day variability than earlier insulins and more prolonged 
duration of action,(10;11) with most expensive basal insulin replacement (iDegl) showing particularly 
low variation and long duration of action.(9) Increased cost of the newer insulins, especially insulin 
iDegl, needs to be balanced against potential improvement in glycaemic control and risk of 
hypoglycaemia.   
There is evidence that, at least in some people, neither iNPH nor iDet nor iGlarg provide 24 hour 
glucose control with a once-daily injection,(12;13) and because of stress laid on flexibility of basal 
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dosing in structured education programmes such as Dose Adjustment For Normal Eating (DAFNE), 
twice-daily basal regimens are increasingly used in clinical practice.(14) Existing economic 
evaluations of basal insulin regimens give conflicting results in terms of the relative cost-effectiveness 
of basal insulin regimens. The most recent review of published economic evaluations of long- and 
intermediate-acting insulin regimens identified 5 economic evaluation studies comparing iNPH with 
iDet.(15-20) Three found that iDet was less costly and more effective; .(17-19) while the other two 
found that iDet was more costly and more effective. Similarly, conflicting results were found for the 
comparison of iNPH with iGlarg (16;20)   None of these studies evaluated iDegl; none compared all 
basal insulin regimens and importantly, none have considered the frequency of daily injections of 
each insulin. Hence, the economic analysis reported in this paper was undertaken to fill the evidence 
gap relative to assess tthe cost effectiveness of all clinically relevant basal insulin regimens available 
for adults with T1D in England; ,the analysis was used to inform the choice of the optimal basal insulin 
regimen to be recommended in the NICE Clinical Guideline NG17 . Insulin glargine 300 IU was not 
available in the UK at the time this work was conducted, so is it was not included. 
Methods 
This CUA was conducted from the perspective of the NHS and Personal Social Services (PSS), with 
quality-adjusted life-years (QALYs) and costs as the main outcome measures. The analysis complied 
with the NICE Reference Case, which is a set of methodological standards specified by NICE 
including using lifetime time horizon and applying discounting at a 3.5% discount rate for both costs 
and QALYs, for costs and outcomes accrued beyond the first year. (21) The reporting also follows the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. No ethics 
approval was required for this study. 
Comparators 
The following insulin regimens were compared against each other: iDet (once daily) (iDet (od)), iDet 
(twice daily) (iDet (bid)), iGlarg 100 IU (once daily) (iGlarg (od)), iDegl (once daily) (iDegl (od)), iNPH 
(once daily) ((iNPH (od)), iNPH (twice daily) ((iNPH (bid)), iNPH (four times daily) ((iNPH (qid)). An 
average daily dose was assumed for all comparators (24 units).(22) This was assumed to be given in 
divided doses for comparators with more than once daily dosing frequency. 
Model description  
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The analysis was undertaken using the IMS CORE Diabetes Model (CDM) Version 8.5.  
The model simulates diabetes progression using a series of interlinked, inter-dependent sub-models 
of the following diabetes complications: angina, myocardial infarction, congestive heart failure, stroke, 
peripheral vascular disease, diabetic retinopathy, macular oedema, cataract, hypoglycaemia, 
ketoacidosis, lactic acidosis, nephropathy and end-stage renal disease, neuropathy, foot ulcer, 
amputation and non-specific mortality. 
These sub-models are Markov models which use time-, state- and diabetes type-dependent 
probabilities that have been derived from published sources. Interaction between the individual 
complication sub-models is mediated through the use of Monte Carlo simulation using tracker 
variables. Full description of the CDM and its modules and sub-models is given in Palmer et al 
(2004).(23) The model has been validated extensively against epidemiological and clinical studies of 
type 1 diabetes.(24) 
The model input parameters are grouped into the following databases: cohort, economics, other 
management, clinical, treatment (clinical effectiveness, costs). The default inputs for T1D were 
validated with the members of the NICE guideline development group (GDG), however, where more 
reliable or recent UK sources were identified through our systematic and/or targeted literature 
reviews, these were used instead. The details of the model parameter inputs used in the analysis and 
their references are provided in the supplementary materials, part 1.(25) 
Simulation cohort 
For the CDM, the population cohort was defined in terms of age, gender, baseline risk factors and 
pre-existing complications, using data that reflected a UK-based, adult, T1D population (Table 1). 
Baseline complications were assumed nil unless reliable UK data could be identified (for example for 
stroke and angina). 
Insert Table 1: Cohort Characteristics 
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Treatment effects 
Two outcomes were used to characterise treatment effects: change in HbA1c from baseline 
(expressed as percentage) and rate of severe hypoglycaemic events.   
Treatment effects for both outcomes were based on a systematic review and network meta-analysis 
(NMA) published separately. Twenty-eight RCTs were included in the review. Two networks were 
constructed and analysed, one for change in HbA1c (25 studies generating 27 comparisons) and one 
for severe/major hypoglycaemic events (16 studies generating 16 comparisons). The included studies 
were systematically identified, assessed and reviewed. The details of the review and NMAs have 
been reported separately. (32) In all included trials, the same bolus insulin was used in both treatment 
arms.  
For the first outcome, change in HbA1c, the mean treatment effect (Table 2) was applied to the cohort 
baseline HbA1c value (8.6%) to specify the level of HbA1c achieved when using each of the insulin 
regimens. The regimen-specific mean rate of severe/major hypoglycaemic events was obtained from 
the NMA results (Table 2). No trials were identified which reportd this outcome for  iNPH (qid)  
therefore, iNPH (qid) was assumed to have the same mean event rate as iNPH (bid). This assumption 
was tested in a sensitivity analysis. 
Insert Table 2: Treatment effects 
Costs 
Only direct costs, i.e. costs of treatment, complications, and diabetes management, were included in 
the analysis. The CDM defaults were updated to reflect current UK costs and clinical practice, where 
appropriate. All costs from sources published before 2013 were inflated to 2013 using the 2012/13 
Hospital and community health services (HCHS) index.(33)  
For treatment costs, only the insulin and needles’ costs were considered as being likely to differ 
among the comparator regimens. The costs of monitoring, nurse time and other consumables were 
considered to be either the same or negligibly different and were not included. Insulin costs were 
calculated using nationally available prices from the British National Formulary (BNF) and MIMS June 
2013,(34) (35) assuming that only cartridges or pre-filled pens were used. An average price was 
calculated for cartridges’ and pre-filled pens’ prices if these were different.  
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The cost of needles, calculated as a weighted average based on the prices of the 10 most commonly 
used needles was £0.11 per needle. (36) The annual treatment cost per patient was calculated as the 
sum of the insulin and the needles’ cost (Table 3). 
Insert Table 3: Treatment costs 
Quality of life (QoL) 
In the CDM, patients with T1D in the absence of complications experience a QoL of 0.814 on a scale 
from 0 to 1. Other events and complications occurring in the model are associated with specific QoL 
(e.g. chronic heart failure, retinopathy, depression, etc) and one-off QoL decrements (e.g. myocardial 
infarction, stroke, etc). The default QoL values of the CDM were used, with the exception of the QoL 
value associated with major hypoglycaemic events, which required adjustment to calculate the 
disutility per episode. This was calculated to be -0.012.(38) All utility and disutility values used are 
listed in the Supplementary material, part 1, Table 2. 
Probabilistic analysis 
The base case analysis was run deterministically and probabilistically. The probabilistic analysis was 
undertaken to assess the impact of parameter uncertainty on the model results, where input 
parameter values were randomly sampled simultaneously using Monte Carlo simulation from relevant 
distributions that are default to the CDM (see Palmer et al (2004) for detail of the distributions 
used.(23)  It was not possible, however, to preserve the correlations between the strategies’ relative 
effectiveness estimates obtained from the NMA as the CDM is not equipped to sample from NMA 
posterior distribution.  
Cost-effectiveness acceptability curves (CEACs) were also constructed to assess decision 
uncertainty; where the probability of being the most cost-effective strategy was plotted against cost-
effectiveness threshold values ranging from £0 to £100,000 for each of the included strategies.  
Sensitivity analysis 
In addition to the probabilistic analysis,  deterministic sensitivity analyses (SAs) were undertaken to 
test the robustness of the model results to changes in assumptions and inputs. In each SA, one or 
more inputs were changed and the analysis rerun to evaluate the impact on results and whether 
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conclusions on which intervention should be recommended would change. Details of the analyses 
SA1 to SA8 are provided in Panel 1.  
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Panel 1: details of the sensitivity analyses  
SA1 - HbA1c progression 
In the base case analysis, the CDM default value for the annual progression in HbA1c was used 
(0.045%). An alternative assumption of no annual progression in HbA1c level (0%) was tested. This 
was done because, in contrast to the case in type 2 diabetes, there is no life-long increase in insulin 
deficiency in T1D, after completion of the honeymoon phase. . 
SA2 - Utility estimation approach 
In the base case analysis, the CDM default “minimum approach” to calculating utility was used. In this 
approach, the quality of life for patients with multiple complications is assumed to take the minimum of 
the utility values associated with these complications. An alternative “multiplicative approach” was 
tested whereby utility for these patients is calculated as a multiplicative function of the utilities for 
these complications.  
SA3 - Rate of severe/major hypoglycaemic events 
In the base case analysis, the rates of severe/major hypoglycaemic events were based on the 
treatment-specific data from the NMA. Since there was a lot of uncertainty around this outcome and 
the NMA did not show any significant difference in hypo event rates between treatments, in a 
sensitivity analysis we assumed no differential effect for any of the comparators on hypoglycaemic 
event rate, effectively considering HbA1c as the only clinical effectiveness outcome measure. The rate 
used for all the treatment was that of iNPH (bid) (35 events per 100 patient-years).  
SA4 - Cohort characteristics  
In the base case analysis, the simulated cohort represented the average population with T1D in the 
UK. A scenario analysis was run assuming a cohort representing a population in the UK with a more 
recent diagnosis of T1D. The alternative cohort characteristics are reported in the table below. 
Cohort characteristics in SA4  
Input variable Value 
Start age (years) 27 
Duration of diabetes (years)  9.10 
Proportion Male  55.2% 
HbA1c (-points) 9.3% 
Systolic Blood Pressure (mmHg) 121.48 
Body mass index (BMI) (kg/m2) 24.90 
Proportion smoker  26% 
SA5- Cost of major hypoglycaemic events 
The cost of a major hypoglycaemic event used in the base case analysis was based on the study by 
Hammer et al (2009)(39) and was estimated to be £333. This was examined in a sensitivity analysis 
where the cost was varied between £0 and £500.  
SA6 - Utility of major hypoglycaemic events 
The base case value (-0.012) was based on an adjustment made to the value reported in the study by 
Currie et al (2006).(38) The original higher value of -0.047 has been used in our one-way sensitivity 
analysis.. 
SA7 - Mortality of major hypoglycaemic events 
The base case mortality due to severe/major hypoglycaemia was varied in a one-way sensitivity 
analysis within a range between 0% and 5%.  
SA8 - Discounting 
The discount rate was varied to 1.5% for both costs and benefits. 
SA9: Insulin doses 
 Regimen-specific daily dose was calculated based on data from the RCTs included in the NMA rather 
than assuming an average dose of 24 units (supplementary material, part 2). 
 SA10: iDet (bid) dose 
 A threshold analysis in which the dose of iDet (bid) was increased relative to other regimens in 5% 
increments, between 105% and 140%, based on the assumption that it is weaker insulin, was also 
carried out. 
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Statistical approach 
The CDM was run probabilistically, with probability distributions defined for each parameter, to take 
account of the uncertainty around the point estimates of the input parameters. In each run, a value for 
each input was randomly selected simultaneously from its respective probability distribution and 
means for costs and QALYs were calculated. The analysis was run repeatedly (1000 times) for the 
base case and results were summarised. Distributions around different parameters are set by default 
in the model and these are explained in the document available on the CDM website.(40) 
The results were presented in terms of net monetary benefit (NMB), (41) calculated by multiplying the 
total QALYs for a comparator by the cost-effectiveness threshold defined by NICE (£20,000/QALY 
gained) and then subtracting the total costs (formula below). The decision rule applied is that the 
comparator with the highest NMB is the most cost-effective option at the specified threshold. This is 
the option that provides the highest number of QALYs at an acceptable cost. Results are also 
presented graphically; where total costs and total QALYs for each regimen are shown on a cost-
effectiveness plane. Comparisons not ruled out by dominance or extended dominance are joined by a 
line on the graph where the slope represents the incremental cost-effectiveness ratio (ICER). (41) 
( ) )()()( XCostsXQALYsXBenefitMonetaryNet -´= l  
Where: λ = threshold (£20,000 per QALY gained) 
Cost-effective if: 
Highest net benefit 
 
Two T1D patients were members in the GDG and contributed to the design, planning and validation of 
model inputs and assumptions. The analysis methods and results were regularly presented to and 
validated by all of the GDG including the two patient members. 
Results 
The results of the base case probabilistic analysis are presented in Table 4. These show that the 
optimal strategy at a cost-effectiveness threshold of £20,000 per QALY was iDet (bid), which was also 
the most effective strategy (highest mean QALYs gained). This strategy was dominant, i.e. it was 
more effective and less costly, compared to two strategies: iDegl (od) and iNPH (qid), it was more 
effective and costly than iDet (od), iGlarg (od), iNPH (od) and iNPH (bid) and a cost-effectiveness 
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threshold of £20,000 per QALY gained, the increased effectiveness justified the increase in costs. The 
incremental analysis results show that iDegl (od), iNPH (qid), iNPH (bid) and iDet (od) were 
dominated strategies. iGlarg (od) was extendedly dominated by a combination of iNPH(od)  and iDet 
(bid);  however if iDet (bid) were not available, the probabilistic ICER of iGlarg (od) compared to iNPH 
(od)  would be £8,605 per QALY, hence iGlarg(od) would be the preferred option. Excluding the 
dominated options, the probabilistic ICER of iDet (bid) vs iNPH (od) was £7,844 per QALY (Figure 1). 
Insert Table 4: Probabilistic base case analysis results 
The CEACs showed that, at cost effectiveness threshold of £20,000 per QALY gained, iDet (bid) had 
the highest probability of being cost effective (26%). This increased to 41% for a cost effectiveness 
threshold of £30,000 per QALY gained and reached a maximum of 42% for threshold values 
>£30,000 per QALY gained (Figure 2).  
The breakdown of the life-time costs per patient shows that the use of iDet (bid) generated a mean 
direct cost higher than use of iGlarg (od), iNPH (bid), iNPH (od) and iDet (od). This was mainly driven 
by the higher cost associated with treatment (£5,074) and longer survival. However, the total costs of 
treating renal complications, ulcer/amputation/neuropathy and eye-related complications were lower 
when using iDet (bid) compared to other insulin regimens.  In fact, the use of iDet (bid) was 
associated with the lowest cost across all comparators in these categories and in the total cost of 
managing all complications (£32,115). This is likely to be due to the better control of HbA1c achieved 
with iDet (bid). The total cost of using iDegl (od) was the highest among the 7 comparators, driven by 
the highest treatment cost (£7,169). 
The SAs’ results (supplementary material, part 2) showed that the model was robust to many changes 
in input parameters in terms of the best ranking strategy. This was the case for SAs 1 to 9.  Changing 
the utility estimation approach (SA2) and the discount rate (SA7) did not lead to any other change in 
the ranking of any of the strategies compared to the base case.  
SA1 (assuming no annual progression in HbA1c), SA3 (changing the rate of severe/major 
hypoglycaemic events), SA4 (changing cohort characteristics), and SA5 (the cost of major/severe 
hypoglycaemic events was assumed to be  £0) resulted in changing the relative ranking of iNPH (od) 
and iNPH (bid), with iNPH (bid) ranking higher than iNPH (od).  
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When mortality of major hypoglycaemic events was assumed to be 5% (SA7) and when the doses 
were based on the RCT doses (SA9), the relative ranking of iDet (od) and iGlarg (od) changed; with 
iDet(od) ranking higher than iGlarg (od). The results of SA10 (supplementary material, part 2), 
showed that while keeping the dose of other insulin regimens to the base case value of 24 units per 
day, the dose of iDet (bid) would have to increase by 30-35% of the base case value for this regimen 
to switch its ranking with iGlarg (od). If this dose is further increased (by 40%), iDet (bid) would be 
ranked third, after both iGlarg (od) and iDet (od), which would rank first and second, respectively. 
Discussion 
The base case probabilistic analysis results, as well as those of all SAs, show that iDet (bid) is the 
most clinically effective basal insulin replacement regimen, with the highest mean QALYs gained over 
life-time time horizon. It was the also the optimal choice in terms of cost-effectiveness, with the 
highest NMB compared with all other long-acting insulin regimens. This was confirmed in all the SAs 
conducted, except when much higher doses were assumed to be required (30% or more compared to 
other regimens).  Thus, the cost effectiveness of  iDet (bid) over iGlarg (od) remained true until the 
required dose of iDet (bid) is more than 125% that of iGlarg (od). The average difference in dose 
estimated from the RCTs included in the NMA was 111%, which is well within this limit.  
iGlarg (od) ranked second in the base case analysis, while iDet (od) was extendedly dominated (i.e. 
was less cost effective than a combination of two other regimens).  However this ranking changed in 
two SAs: when using the long-acting insulin regimen daily dose from the RCTs (SA9) and when the 
mortality from major hypoglycaemic events was increased to 5% (compared to 0% in the base case, 
SA7). In both these SAs, iDet (od) ranked second followed by iGlarg (od).   In the former analysis 
(SA9), this change in ranking resulted from a change in the ICER of iGlarg (od) compared to iDet (od) 
which was calculated to be £28,500 per QALY gained, slightly above the NICE cost-effectiveness 
threshold of £20,000 per QALY gained, creating some uncertainty around the superiority of iGlarg 
(od) over iDet (od) in terms of cost effectiveness. 
Results from published economic evaluations report conflicting results in relation of the relative cost-
effectiveness of basal insulin regimens, with five cost-utility analyses (CUAs) showing that iDet was 
cost effective compared to iNPH at a cost-effectiveness threshold of £20,000 per quality-adjusted life-
year  (QALY) gained, (18;20;42-44) while another found that iDet was not cost effective. (16) Three 
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CUAs found that iGlarg was cost effective compared to iNPH,(45-47) another found that iGlarg was 
dominant compared to iNPH,(48) while another found that iGlarg was not cost effective compared to 
iNPH.(16) One CUA found that iDet was dominant (less costly and more effective) over iGlarg, (44) 
while another found that iGlarg was the dominant option when compared to iDet.(16)  
The results of our economic analysis are in line with the findings from some of these previously 
published cost-utility analyses, which found that iDet was cost effective compared to iNPH (ICERs: 
£2,500, £3,443, £9,526, £12,989 and £19,285 per QALY gained),(18;20;42-44) iGlarg was cost 
effective compared to iNPH (ICERs: £3,496 - £4,978, £3,189 - £9-767 and £10,903 per QALY 
gained),(45-47) and one study finding that iDet was dominant (less costly and more effective) over 
iGlarg. (44) However, this last analysis and ours conflict with that of Cameron and colleagues, (16) 
which concluded that iGlarg dominated iDet. This is likely to be due to two main reasons. The first is 
the fact that drug prices in Canada are very different from those in Europe. The ratio of cost between 
iDet or iGlarg and NPH and similarly the ratio of cost between iDet and iGlarg are much higher in 
Canada than in UK. The second is the difference in the clinical effectiveness evidence used to inform 
the models in the two studies. In Cameron and colleagues’ analysis,(16) the clinical effectiveness 
estimates used in the model were based on a direct meta-analysis (MA) combining results from trials 
that compared each of iGlarg and iDet versus iNPH. This MA showed that iGlarg was more effective 
than iDet in terms of HbA1c reduction (-0.11% versus -0.06%, respectively, compared to iNPH but did 
not consider iDet (od) and iDet (bid) regimens separately. In contrast, our economic analysis utilises 
clinical effectiveness estimates from our NMA which took into account iDet frequency of 
administration and provided estimates of relative treatment effects for all 7 basal insulin regimens. To 
our knowledge, our study is the first original economic analysis to assess the comparative cost 
effectiveness of the different frequencies of basal insulin administration. 
Our study had some limitations. There is, inevitably, uncertainty around some of the model parameter 
inputs.  However, the model results were tested in a wide range of SAs which showed consistent 
results for the optimal choice [iDet (bid)], with less certainty around the choice of iGlarg (od) and iDet 
(od) as the second and third best options. We were also not able to include the impact of the insulin 
regimens on minor hypoglycaemia, defined as episodes of hypoglycaemia that does not require 
assistance from third party, and body weight due to the lack of a coherent estimate effect to use in 
13	
	
populating the model. It is also not clear how minor hypoglycaemia impacts on health related quality 
of life. There were also some limitations of the CDM used. In version 8.5, there is no possibility of 
including nocturnal hypoglycaemia as an outcome when characterising treatment effects. This has 
been addressed in the latest release (version 9.0). The model also includes parameters that are not 
specific to a T1D population, utilising some data from the T2D population. Where data were available, 
we modified the CDM to use T1D data. Reduction in HbA1c, which is the main outcome measure of 
the CDM, is an intermediate outcome; however; it is considered to be a reliable proxy measure of 
disease progression and complications. Its link to the most important clinical outcomes for diabetes 
patients, including complications and mortality is well established and validated. (2;5)  Patient 
adherence and possible disutility due to multiple daily injections were not included in the model as it 
was believed that adults with T1D generally tolerate increased injection frequency if this provides 
better control of their diabetes and reduced risk of hypoglycaemia, with no negative effect on the 
treatment adherence or quality of life.(49) This was confirmed with the patient members of the GDG. 
Adults with T1D already use multiple injections of short acting insulin and it is not anticipated that 
there would be further disutility associated with increased frequency of basal insulin administration.  
Disutility due to fear of hypoglycaemia was also not explicitly included in the model. However, the 
utility value associated with suffering a major hypoglycaemic event already incorporates this 
disutility.(38) A further limitation of the CDM in relation to this model is that it does not have the ability 
to use the simulation results from the NMA in the probabilistic analysis runs. This is important as 
independent sampling from the NMA could lead to implausible sets of parameters in some PSA runs. 
Finally, this original economic analysis is directly applicable to the adult T1D population in England. 
Generalisability of its findings to the paediatric population or T1D populations in other settings may 
not be appropriate.  
Our results suggest that further research is needed to reduce the uncertainty around the estimates of 
disutility and mortality associated with severe hypoglycaemic events, given the sensitivity of the model 
results to these parameters. Nevertheless, this analysis provides a hierarchy for currently available 
basal insulin regimens in terms of their cost effectiveness, which can guide prescribing decisions and 
be used to inform NICE guideline recommendation regarding the choice of an optimal regimen for 
patients in England. 
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Conclusion 
This study showed that, from the perspective of the English NHS, iDet (bid) is the most cost-effective 
basal insulin regimen for people with T1D, within the range of basal insulin doses seen in clinical 
trials. iGlarg (od) or iDet (od) are likely to be cost effective for patients for whom iDet (bid) is not an 
option. This is the first study to assess the relative cost effectiveness of different frequencies of 
administration of the same insulin.  
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